“三医联动新生态”大会8城同启 阿美替尼肺癌辅助治疗医保落地

Core Insights - The conference titled "New Ecosystem of Three Medical Linkages" was held to discuss clinical innovation and technology empowerment in healthcare, supported by Jiangsu Haosen Pharmaceutical and organized by the China Medical Education Association [1] - The third-generation EGFR-TKI drug, Amivantamab, has been officially included in the new national medical insurance directory for postoperative adjuvant therapy of EGFR mutation-positive non-small cell lung cancer (NSCLC), marking a significant advancement in accessibility for patients [1] Group 1 - The conference emphasized the importance of "Three Medical Linkages" as a core approach to deepen healthcare reform and promote the Healthy China initiative, with experts advocating for collaborative efforts to maximize policy benefits and innovation outcomes [2] - Experts discussed the strategic layout of the national policy encouraging pharmaceutical innovation, optimizing drug review and approval processes, and improving medical insurance payment mechanisms, providing clear policy expectations for the development and application of innovative drugs [2] - The conference highlighted the challenges of lung cancer, which has the highest incidence and mortality rates among malignant tumors in China, with approximately 85% of cases being NSCLC and about 30% of patients diagnosed at an operable early stage facing postoperative recurrence risks [2] Group 2 - The rapid development of Chinese-origin third-generation EGFR-TKI drugs, represented by Amivantamab, offers new options for postoperative adjuvant therapy in early-stage NSCLC, with evidence from the ART study supporting its efficacy for patients in stages II to IIIB [3] - The inclusion of Amivantamab in the national medical insurance directory significantly enhances its affordability, reducing treatment disparities among patients from different regions and economic backgrounds, and facilitating the distribution of quality targeted therapy resources to grassroots medical institutions [3]